Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.60 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15850892 | 0.89 | CACNA1B (0.72) | CACNA1BCACNA1CCACNA1GCACNA1HHTR2C | |
| SCHEMBL20088381 | 0.85 | CACNA1H (0.42) | CACNA1BCACNA1CCACNA1GCACNA1HDRD1 | |
| SCHEMBL20088399 | 0.84 | CACNA1H (0.58) | CACNA1BCACNA1CCACNA1GCACNA1HDRD1 | |
| SCHEMBL20088402 | 0.84 | CACNA1H (0.44) | CACNA1BCACNA1CCACNA1GCACNA1HDRD1 | |
| SCHEMBL20088400 | 0.83 | CACNA1H (0.42) | CACNA1BCACNA1CCACNA1GCACNA1HDRD1 | |
| SCHEMBL20088391 | 0.81 | CACNA1H (0.36) | CACNA1BCACNA1CCACNA1GCACNA1HCCNE1 | |
| SCHEMBL20088386 | 0.81 | CACNA1H (0.61) | CACNA1BCACNA1CCACNA1GCACNA1HDRD1 | |
| SCHEMBL20088401 | 0.77 | NLRP3 (0.35) | CACNA1BCACNA1CCACNA1GCACNA1HTDP1 | |
| SCHEMBL20088395 | 0.77 | CACNA1H (0.38) | CACNA1BCACNA1CCACNA1GCACNA1HTDP1 | |
| SCHEMBL16186538 | 0.76 | CACNA1G (0.54) | CACNA1BCACNA1CCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | CACNA1B 25/4885CACNA1C 49/4885CACNA1G 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.